Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn’s disease and ulcerative colitis

Objective: The infliximab biosimilar CT-P13 (Remsima(®), Inflectra(®)) was approved in Europe for the treatment of inflammatory bowel disease (IBD) based on extrapolation of data from patients with rheumatic disease. Because there are limited published reports on clinical outcomes for IBD patients t...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Scand J Gastroenterol
Main Authors: Keil, Radan, Wasserbauer, Martin, Zádorová, Zdena, Hajer, Jan, Drastich, Pavel, Wohl, Pavel, Beneš, Marek, Bojková, Martina, Svoboda, Pavel, Konečný, Michal, Falt, Přemysl, Vaňásek, Tomáš, Pešta, Martin, Pešek, František, Bouchner, Luděk, Koželuhová, Jana, Novotný, Aleš, Bartůsková, Lucie, Špičák, Julius
Formato: Artigo
Idioma:Inglês
Publicado: Taylor & Francis 2016
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4926778/
https://ncbi.nlm.nih.gov/pubmed/27002981
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/00365521.2016.1149883
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares